The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 101–200 of 2,716
Prete, A., Subramanian, A., Bancos, I., Chortis, V., Tsagarakis, S., Lang, K., Macech, M., Delivanis, D. A., Pupovac, I. D., Reimondo, G., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-1737 · Cited by 154
“We included all EURINE-ACT participants who were diagnosed with benign adrenocortical adenomas and had standardized endocrine assessment for exclusion of cortisol excess (9, 10); measurement of endocrine parameters was done in the recruitment center.”
MethodVilar, L., Naves, L. A., Azevedo, M. F., Arruda, M. J., Arahata, C. M., Silva, L. M. E., Agra, R., Pontes, L., Montenegro, L., Albuquerque, J. L., et al. (2009) · Pituitary · doi:10.1007/s11102-009-0209-8 · Cited by 154
“Unlike prolactinomas and acromegaly, currently there is not an effective medication to treat Cushing’s disease that acts at the level of the pituitary gland inhibiting ACTH secretion by the corticotroph tumor [1, 2 ]. Some neuromodulatory drugs were used in the past, however, due to”
BackgroundEndoscopic endonasal transsphenoidal surgery for functional pituitary adenomas
Hofstetter, C. P., Shin, B. J., Mubita, L. L., Huang, C., Anand, V. K., Boockvar, J. A., & Schwartz, T. H. (2011) · Neurosurgical FOCUS · doi:10.3171/2011.1.focus10317 · Cited by 152
High variability in baseline urinary free cortisol values in patients with Cushing's disease
Petersenn, S., Newell‐Price, J., Findling, J. W., Gu, F., Maldonado, M., Sen, K., Salgado, L. R., Colao, A., Biller, B. M. K., & Pasireotide B2305 Study Group (2014) · Clinical Endocrinology · doi:10.1111/cen.12259 · Cited by 150
“9 A systematic review and meta-analysis of the literature on diagnostic tests for Cushing’s syndrome showed that UFC and overnight DST have the most evidence to support their use, although the receiver operator characteristic curves for UFC were slightly inferior to those for DST. 10 Despite…”
InfluentialSelf-citationConventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review
Isidori, A. M., Sbardella, E., Zatelli, M. C., Boschetti, M., Vitale, G., Colao, A., Pivonello, R., * ABC (Altogether to Beat Cushing's syndrome) 2013 Group collaborators, Albiger, N., Ambrogio, A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1589 · Cited by 150
“The status of The Endocrine Society.”
InfluentialLopez, D., Luque-Fernandez, M. A., Steele, A., Adler, G. K., Turchin, A., & Vaidya, A. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0547 · Cited by 145
“Subclinical hypercortisolism was defined by the DST in 21 of 25 (mean postdexamethasone cortisol level, 77 nmol/L) and by 24-hour UFC level in 4 of 25 (mean UFC level, 201 nmol).”
BackgroundMethodInfluentialRaff, H., Sharma, S. T., & Nieman, L. K. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130035 · Cited by 141
Self-citationSelective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
Eller-Vainicher, C., Morelli, V., Ulivieri, F. M., Palmieri, S., Zhukouskaya, V. V., Cairoli, E., Pino, R., Naccarato, A., Scillitani, A., Beck-Peccoz, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1648 · Cited by 143
“Indeed, the definition of SH is still controversial, due to the lack of specific signs and symptoms (by definition) of subclinical cortisol excess and to the possible fluctuation of cortisol secretion over time in AI patients.((2,35)) The difficulty in differentiating patients with and without SH explains, at least in…”
BackgroundVeytsman, I., Nieman, L., & Fojo, T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2775 · Cited by 142
Self-citationRossi, G. P., Bisogni, V., Rossitto, G., Maiolino, G., Cesari, M., Zhu, R., & Seccia, T. M. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00415-9 · Cited by 201
“On history, excessive use of exogenous glucocorticoid leading to iatrogenic CS must be ruled out before considering screening tests, which are indicated in the following categories of hypertensives: (1) patients with unusual features, for example, osteoporosis at a young age; (2) patients with suggestive signs and sym…”
BackgroundSteroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., et al. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00262 · Cited by 141
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Perogamvros, I., Owen, L. J., Newell-Price, J., Ray, D. W., Trainer, P. J., & Keevil, B. G. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.09.014 · Cited by 140
Self-citationBen-Shlomo, A., & Cooper, O. B. (2018) · Pituitary · doi:10.1007/s11102-018-0864-8 · Cited by 139
Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics
Keil, M. F., & Stratakis, C. A. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.563 · Cited by 139
Guidelines for the management of the incidentally discovered adrenal mass
Kapoor, A., Morris, T., & Rebello, R. (2011) · Canadian Urological Association Journal · doi:10.5489/cuaj.11135 · Cited by 140
Salivary cortisol and cortisone in the clinical setting
Blair, J., Adaway, J., Keevil, B., & Ross, R. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000328 · Cited by 138
Manetti, L., Bogazzi, F., Giovannetti, C., Raffaelli, V., Genovesi, M., Pellegrini, G., Ruocco, L., Iannelli, A., & Martino, E. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0583 · Cited by 138
Medical and Surgical Evaluation and Treatment of Adrenal Incidentalomas
Zeiger, M. A., Siegelman, S. S., & Hamrahian, A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0085 · Cited by 135
“Despite the lack of a single “gold standard” test to diagnose SCS, the authors consider a combination of the 1-mg DST and plasma ACTH level as the best diagnostic tool for evaluation of patients suspected to have SCS (20, 21, 48).”
BackgroundFindling, J. W., & Raff, H. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0946 · Cited by 134
Self-citationNovel liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for measuring steroids
Keevil, B. G. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.015 · Cited by 157
Biochemical Testing for Neuroendocrine Tumors
Vinik, A. I., Silva, M. P., Woltering, G., W. Go, V. L., Warner, R., & Caplin, M. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181bc0e77 · Cited by 133
“In some cases, a serum midnight cortisol or dexamethasone corticotropin-releasing hormone test should be done.(56)”
BackgroundLiu, N., Jiang, H., Ben-Shlomo, A., Wawrowsky, K., Fan, X., Lin, S., & Melmed, S. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018091108 · Cited by 140
“Finally, chronic hypercortisolism exerts specific myocardial effects leading to increased ventricular wall thickness, with subsequent systolic and diastolic dysfunction contributing to high risk of heart failure in patients with Cushing disease (1, 29).”
BackgroundAldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism
Späth, M. R., Korovkin, S., Antke, C., Anlauf, M., & Willenberg, H. S. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1070 · Cited by 137
Nunes, M.-L., Vattaut, S., Corcuff, J.-B., Rault, A., Loiseau, H., Gatta, B., Valli, N., Letenneur, L., & Tabarin, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1542 · Cited by 129
Subclinical Cushing’s syndrome: definition and management
Terzolo, M., Pia, A., & Reimondo, G. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04253.x · Cited by 130
A comprehensive diagnostic approach to detect underlying causes of obesity in adults
van der Valk, E. S., van den Akker, E. L. T., Savas, M., Kleinendorst, L., Visser, J. A., Van Haelst, M. M., Sharma, A. M., & van Rossum, E. F. C. (2019) · Obesity Reviews · doi:10.1111/obr.12836 · Cited by 129
Clinical 7 T MRI: Are we there yet? A review about magnetic resonance imaging at ultra-high field
Barisano, G., Sepehrband, F., Ma, S. J., Jann, K., Cabeen, R. P., Wang, D. J. J., Toga, A. W., & Law, M. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180492 · Cited by 151
Debono, M., Harrison, R. F., Whitaker, M. J., Eckland, D., Arlt, W., Keevil, B. G., & Ross, R. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3694 · Cited by 128
“They are therefore used extensively in hospital laboratories (22), are an ideal tool for researchers, and the measurement of salivary cortisol has been recommended in major guidelines (3).”
BackgroundMethodThe Physiologic Effects of Pain on the Endocrine System
Tennant, F. S. (2013) · Pain and Therapy · doi:10.1007/s40122-013-0015-x · Cited by 160
Giordano, R., Picu, A., Marinazzo, E., D’Angelo, V., Berardelli, R., Karamouzis, I., Forno, D., Zinnà, D., Maccario, M., Ghigo, E., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04055.x · Cited by 122
Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement
Young, W. F., Calhoun, D. A., Lenders, J. W. M., Stowasser, M., & Textor, S. C. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00054 · Cited by 145
“The Endocrine Society’s clinical practice guideline on Cushing syndrome further details tests that confirm Cushing syndrome and determine the cause of cortisol excess (95).”
BackgroundSubclinical hypercortisolism: a state, a syndrome, or a disease?
Di Dalmazi, G., Pasquali, R., Beuschlein, F., & Reincke, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0272 · Cited by 123
Manenschijn, L., Koper, J. W., van den Akker, E. L. T., de Heide, L. J. M., Geerdink, E. A. M., de Jong, F. H., Feelders, R. A., & van Rossum, E. F. C. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1852 · Cited by 122
“Standardscreening tests forCSare themeasurement of cortisol in 24-h urinary collections, the measurement of cortisol inmidnightsalivaandthe1-mgovernightdexamethasonesuppressiontest (2).”
BackgroundMethodClinical characteristics of patients with resistant hypertension: the RESIST-POL study
Florczak, E., Prejbisz, A., Szwench-Pietrasz, E., Śliwiński, P., Bieleń, P., Klisiewicz, A., Michałowska, I., Warchoł, E., Januszewicz, M., Kała, M., et al. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.32 · Cited by 120
Di Dalmazi, G., Kisker, C., Calebiro, D., Mannelli, M., Canu, L., Arnaldi, G., Quinkler, M., Rayes, N., Tabarin, A., Laure Jullié, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2152 · Cited by 119
“The absence of differences in urinary free cortisol and midnight cortisol is not fully consistent with the values of cortisol after DST, but may be explained mainly by the lack of complete hormonal data for all patients, and partly by the sensitivity and the specificity of these tests that could be affected, especiall…”
Results of Gamma Knife surgery for Cushing's disease: Clinical article
Sheehan, J. P., Xu, Z., Salvetti, D. J., Schmitt, P. J., & Vance, M. L. (2013) · Journal of Neurosurgery · doi:10.3171/2013.7.jns13217 · Cited by 118
Pivonello, R., Petersenn, S., Newell‐Price, J., Findling, J. W., Gu, F., Maldonado, M., Trovato, A., Hughes, G., Salgado, L. R., Lacroix, A., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12431 · Cited by 117
Self-citationCushing's syndrome: Overview of clinical presentation, diagnostic tools and complications
Barbot, M., Zilio, M., & Scaroni, C. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101380 · Cited by 116
Iñiguez-Ariza, N. M., Kohlenberg, J. D., Delivanis, D. A., Hartman, R. P., Dean, D. S., Thomas, M. A., Shah, M. Z., Herndon, J., McKenzie, T. J., Arlt, W., et al. (2018) · Mayo Clinic Proceedings: Innovations, Quality & Outcomes · doi:10.1016/j.mayocpiqo.2017.11.002 · Cited by 116
“Age at diagnosis (y), median (range) 55 (18-87) 64 (18-91) <.”
Cushing’s Syndrome in Pediatrics
Lodish, M. B., Keil, M. F., & Stratakis, C. A. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.008 · Cited by 116
Arnaldi, G., & Boscaro, M. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.12.006 · Cited by 133
Jung, C., Greco, S., Nguyen, H. H., Ho, J. T., Lewis, J. G., Torpy, D. J., & Inder, W. J. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-91 · Cited by 114
“Exclusion criteria were preexisting Cushing’s syndrome, adrenal insufficiency, renal impairment, psychiatric disorders, alcoholism, pregnancy, and the use of glucocorticoid medication, oestrogen or drugs known to affect the metabolism of hydrocortisone [31] or dexamethasone [32].”
BackgroundHormonal activity of adrenal incidentalomas: results from a long-term follow-up study
Vassilatou, E., Vryonidou, A., Michalopoulou, S., Manolis, J., Caratzas, J., Phenekos, C., & Tzavara, I. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03492.x · Cited by 112
Potential Role for Retinoic Acid in Patients with Cushing's Disease
Pecori Giraldi, F., Ambrogio, A. G., Andrioli, M., Sanguin, F., Karamouzis, I., Corsello, S. M., Scaroni, C., Arvat, E., Pontercorvi, A., & Cavagnini, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2328 · Cited by 113
Barbot, M., Albiger, N. M. E., Ceccato, F., Zilio, M., Frigo, A. C., Denaro, L., Mantero, F., & Scaroni, C. M. (2013) · Pituitary · doi:10.1007/s11102-013-0475-3 · Cited by 121
Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion
Gerards, J., Heinrich, D. A., Adolf, C., Meisinger, C., Rathmann, W., Sturm, L., Nirschl, N., Bidlingmaier, M., Beuschlein, F., Thorand, B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00299 · Cited by 112
Antonelli, G., Ceccato, F., Artusi, C., Marinova, M., & Plebani, M. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.004 · Cited by 111
Role of biomarker tests for diagnosis of neuroendocrine tumours
Hofland, J., Zandee, W. T., & de Herder, W. W. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0082-5 · Cited by 129
Dimopoulou, C., Schopohl, J., Rachinger, W., Buchfelder, M., Honegger, J., Reincke, M., & Stalla, G. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0634 · Cited by 110
Storr, H. L., Alexandraki, K. I., Martin, L., Isidori, A. M., Kaltsas, G. A., Monson, J. P., Besser, G. M., Matson, M., Evanson, J., Afshar, F., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1120 · Cited by 110
Self-citationKamp, K., Alwani, R. A., Korpershoek, E., Franssen, G. J. H., de Herder, W. W., & Feelders, R. A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0968 · Cited by 116
The incidence of endogenous Cushing's syndrome in the modern era
Wengander, S., Trimpou, P., Papakokkinou, E., & Ragnarsson, Ó. (2019) · Clinical Endocrinology · doi:10.1111/cen.14014 · Cited by 127
Specificity of Screening Tests for Cushing’s Syndrome in an Overweight and Obese Population
Baid, S. K., Rubino, D., Sinaii, N., Ramsey, S., Frank, A., & Nieman, L. K. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2766 · Cited by 105
Self-citationNardo, F. D., Cavalera, S., Baggiani, C., Giovannoli, C., & Anfossi, L. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b11559 · Cited by 109
The Importance of the Biological Impact of Exposure to the Concept of the Exposome
Dennis, K. K., Auerbach, S. S., Balshaw, D. M., Cui, Y., Fallin, M. D., Smith, M. T., Spira, A., Sumner, S., & Miller, G. W. (2016) · Environmental Health Perspectives · doi:10.1289/ehp140 · Cited by 103
Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis
van Hulsteijn, L. T., Pasquali, R., Casanueva, F., Haluzik, M., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0666 · Cited by 103
Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis
Carroll, T., Raff, H., & Findling, J. W. (2009) · Endocrine Practice · doi:10.4158/ep09023or · Cited by 100
Self-citationGuignat, L., & Bertherat, J. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0627 · Cited by 101
Iacobone, M., Citton, M., Viel, G., Boetto, R., Bonadio, I., Mondi, I., Tropea, S., Nitti, D., & Favia, G. (2012) · Surgery · doi:10.1016/j.surg.2012.08.054 · Cited by 101
Kamba, A., Daimon, M., Murakami, H., Otaka, H., Matsuki, K., Sato, E., Tanabe, J., Takayasu, S., Matsuhashi, Y., Yanagimachi, M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166077 · Cited by 100
Accuracy of laboratory tests for the diagnosis of Cushing syndrome
Galm, B. P., Qiao, N., Klibanski, A., Biller, B. M. K., & Tritos, N. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa105 · Cited by 100
Self-citationDebono, M., Harrison, R. F., Chadarevian, R., Gueroult, C., Abitbol, J.-L., & Newell-Price, J. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00823 · Cited by 100
“Although an ONDST cut-off of serum cortisol of 50 nmol/L is recommended by both the Endocrine Society and European Society of Endocrinology to identify hypercortisolemia in AI (5, 12), other data suggest that a lower level of serum cortisol may be associated with true normality.”
BackgroundSelf-citationGiordano, R., Marinazzo, E., Berardelli, R., Picu, A., Maccario, M., Ghigo, E., & Arvat, E. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0957 · Cited by 99
ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy
Luger, A., Broersen, L. H. A., Biermasz, N. R., Biller, B. M. K., Buchfelder, M., Chanson, P., Jørgensen, J. O. L., Keleştimur, F., Llahana, S., Maiter, D. M., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0462 · Cited by 112
Self-citationBerr, C. M., Di Dalmazi, G., Osswald, A., Ritzel, K., Bidlingmaier, M., Geyer, L. L., Treitl, M., Hallfeldt, K., Rachinger, W., Reisch, N., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3632 · Cited by 99
“Diagnosis of CS and subtype differentiation was established according to current guidelines (11, 12).”
MethodSilent Corticogonadotroph Adenomas: Clinical and Cellular Characteristics and Long-Term Outcomes
Cooper, O. B., Ben-Shlomo, A., Bonert, V. S., et al. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0014-x · Cited by 98
“Corticotroph adenomas (∼10% of pituitary tumors) are immunopositive for adrenocorticotrophic hormone (ACTH) and are associated with elevated circulating ACTH and cortisol levels leading to Cushing’s disease with features of hypercortisolism [3, 4].”
Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests
Alwani, R. A., Schmit Jongbloed, L. W., de Jong, F. H., van der Lely, A. J., de Herder, W. W., & Feelders, R. A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0702 · Cited by 98
Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome
Eisenhofer, G., Masjkur, J., Peitzsch, M., Di Dalmazi, G., Bidlingmaier, M., Grüber, M., Fazel, J., Osswald, A., Beuschlein, F., & Reincke, M. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.282582 · Cited by 96
Investigation and management of subfertility
Thurston, L., Abbara, A., & Dhillo, W. S. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205579 · Cited by 110
“…rare cause of menstrual disturbance with hyperandrogenism and weight gain, but if clinically suspected (reddish purple striae, plethora, proximal muscle weakness, bruising with no obvious trauma and unexplained osteoporosis), 12 referral to an endocrinologist for further assessment is recommended.”
Reel, P. S., Reel, S., van Kralingen, J. C., Langton, K., Lang, K., Erlic, Z., Larsen, C. K., Amar, L., Pamporaki, C., Mulatero, P., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104276 · Cited by 112
Mechanick, J. I., Camacho, P. M., Cobin, R. H., Garber, A. J., Garber, J. R., Gharib, H., Petak, S. M., Rodbard, H. W., & Trence, D. L. (2010) · Endocrine Practice · doi:10.4158/ep.16.2.270 · Cited by 96
Akehi, Y., Yanase, T., Motonaga, R., Umakoshi, H., Tsuiki, M., Takeda, Y., Yoneda, T., Kurihara, I., Itoh, H., Katabami, T., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1293 · Cited by 95
“This study was presented in poster form at ENDO 2019, the Endocrine Society’s Annual Meeting, New Orleans, LA, 23–26 March 2019.”
BackgroundInfluentialSerum cortisol: an up-to-date assessment of routine assay performance
Hawley, J. M., Owen, L. J., Lockhart, S. J., Monaghan, P. J., Armston, A., Chadwick, C. A., Wilshaw, H., Freire, M., Perry, L., & Keevil, B. G. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255034 · Cited by 95
COVID-19 and the Endocrine System: A Comprehensive Review on the Theme
Lisco, G., Tullio, A. D., Stragapede, A., Solimando, A. G., Albanese, F., Capobianco, M., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Vacca, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132920 · Cited by 110
“From a diagnostic point of view, more emphasis must be given to the crucial clinical hallmarks of CS to investigate only cases in which a cortisol excess diagnosis would be more likely [227].”
BackgroundKuruppu, D. K., & Matthews, B. R. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359320 · Cited by 119
High-resolution daily profiles of tissue adrenal steroids by portable automated collection
Upton, T. J., Zavala, E., Methlie, P., Kämpe, O., Tsagarakis, S., Øksnes, M., Bensing, S., Vassiliadi, D. A., Grytaas, M. A., Botusan, I. R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg8464 · Cited by 94
Ueland, G. Å., Methlie, P., Kellmann, R., Bjørgaas, M., Åsvold, B. O., Thorstensen, K., Kelp, O., Thordarson, H. B., Mellgren, G., Løvås, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0078 · Cited by 94
The diagnosis of Cushing’s syndrome
Carroll, T. B., & Findling, J. W. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9143-3 · Cited by 108
“They include facial plethora, easy bruising, violaceous striae, as well as proximal muscle weakness [2].”
BackgroundInfluentialSelf-citationScott-Brown’s Otorhinolaryngology Head and Neck Surgery
Sathyapalan, T., & Atkin, S. L. (2018) · CRC Press eBooks · doi:10.1201/9780203731031 · Cited by 94
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome
Newell-Price, J. D. C., Nieman, L. K., Reincke, M., & Tabarin, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0352 · Cited by 97
Self-citationGenetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation
Ronchi, C. L., Di Dalmazi, G., Faillot, S., Sbiera, S., Assié, G., Weigand, I., Calebiro, D., Schwarzmayr, T., Appenzeller, S., Rubin, B., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1586 · Cited by 93
Diagnosis and complications of Cushing’s disease: gender-related differences
Zilio, M., Barbot, M., Ceccato, F., Camozzi, V., Bilora, F., Casonato, A., Frigo, A. C., Albiger, N., Daidone, V., Mazzai, L., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12299 · Cited by 93
Methlie, P., Hustad, S., Kellman, R., Almås, B., Erichsen, M. M., Husebye, E. S., & Løvås, K. (2013) · Endocrine Connections · doi:10.1530/ec-13-0023 · Cited by 92
Diagnosis of Cushing’s Syndrome in the Modern Era
Nieman, L. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.001 · Cited by 93
Self-citationEvaluation of depression, quality of life and body image in patients with Cushing’s disease
Alçalar, N., Ozkan, S., Kadıoğlu, P., Celik, O., Çağatay, P., Küçükyürük, B., & Gazioğlu, N. (2012) · Pituitary · doi:10.1007/s11102-012-0425-5 · Cited by 95
Neary, N. M., Booker, O. J., Abel, B. S., Matta, J. R., Muldoon, N., Sinaii, N., Pettigrew, R. I., Nieman, L. K., & Gharib, A. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3754 · Cited by 92
“CS was diagnosed in 15 subjects by clinical history and examination and by measuring 24-hour urine free cortisol excretion (UFC) and late-night serum cortisol levels (10).”
BackgroundSelf-citationElias, P. C. L., Martinez, E. Z., Barone, B. F. C., Mermejo, L. M., Castro, M., & Moreira, A. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4262 · Cited by 90
Broder, M. S., Neary, M. P., Chang, E. Y., Cherepanov, D., & Ludlam, W. H. (2014) · Pituitary · doi:10.1007/s11102-014-0569-6 · Cited by 113
“Disease recurrence can be treated by repeat operation, radioablation, or medical treatment [2, 5].”
BackgroundYanase, T., Oki, Y., Katabami, T., Otsuki, M., Kageyama, K., Tanaka, T., Kawate, H., Tanabe, M., Doi, M., Akehi, Y., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej17-0456 · Cited by 90
“Except for the guideline from Endocrine Society (USA), all non-Japanese guidelines have not adopted salivary cortisol as a screening test [13-15].”
BackgroundInfluentialTirabassi, G., Faloia, E., Papa, R., Furlani, G., Boscaro, M., & Arnaldi, G. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1146 · Cited by 90
Terzolo, M., Reimondo, G., Chiodini, I., Castello, R., Giordano, R., Ciccarelli, E., Limone, P., Crivellaro, C., Martinelli, I., Montini, M., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1323 · Cited by 89
“In a multiple regression analysis including as candidate predictive variables age, BMI, systolic and diastolic blood pressure, glycosilated hemoglobin (HbA1c) and fasting glucose levels, post-DST cortisol levels were associated with systolic blood pressure (=0.09, P=0.02) and HbA1c values (=0.12, P=0.001).”
BackgroundMethodInfluentialWagenmakers, M. A. E. M., Boogaarts, H. D., Roerink, S. H. P. P., Timmers, H. J. L. M., Stikkelbroeck, N. M. M. L., Smit, J. W. A., van Lindert, E. J., Netea-Maier, R. T., Grotenhuis, J. A., & Hermus, A. R. M. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0325 · Cited by 89
Clinical presentation and etiology of Cushing's syndrome: Data from ERCUSYN
Valassi, E. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13114 · Cited by 89
“In particular, a significant overlap may exist between some features associated with hypercortisolism and those commonly found in the general population.(3) As a result, time elapsed to diagnosis can be considerably large, increasing the burden of the disease and contributing to maintain multiple comorbidities, poor q…”
BackgroundCushing’s Syndrome: All Variants, Detection, and Treatment
Sharma, S. T., & Nieman, L. K. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.01.006 · Cited by 89
“guidelines, any of the following tests can be used for the initial diagnosis of Cushing’s syndrome: 24-hour urinary free cortisol, late-night salivary cortisol, or a dexamethasone suppression test (DST, either as a 1-mg overnight test or the longer low-dose test using 2 mg/d over 48 hours).(9)”
MethodSelf-citationThe diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline
Nieman, L., Biller, B., Findling, J., Newell-Price, J., Savage, M., Stewart, P., & Montori, V. M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0695 · Cited by 90
“104 I Clin Biochem Rev Vol 29 November 2008 night salivary cortisol; ( 3 ) 1 mg overnight DST or (4) longer low dose DST (2 mg/day for 48 h). Individual patient characteristics may help to determine test choice.”
BackgroundSelf-citationApproach to the Patient: Diagnosis of Cushing Syndrome
Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac492 · Cited by 91
“Patients who have multiple symptoms, which are progressive over time, in particular when specific cushingoid features are present (3).”
BackgroundInfluentialA genetic and molecular update on adrenocortical causes of Cushing syndrome
Lodish, M. B., & Stratakis, C. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.24 · Cited by 97
Cushing Syndrome: Maybe Not So Uncommon of an Endocrine Disease
Guaraldi, F., & Salvatori, R. (2012) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2012.02.110227 · Cited by 87
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.